WO2025125577 - ANTIBODIES AGAINST INFLUENZA B VIRUS
National phase entry is expected:
Publication Number
WO/2025/125577
Publication Date
19.06.2025
International Application No.
PCT/EP2024/086236
International Filing Date
13.12.2024
Title **
[English]
ANTIBODIES AGAINST INFLUENZA B VIRUS
[French]
ANTICORPS DIRIGÉS CONTRE LE VIRUS DE LA GRIPPE B
Applicants **
VIB VZW
UNIVERSITEIT GENT
Inventors
SAELENS, Xavier
MATTHYS, Arne
SAVVIDES, Savvas
FELIX, Jan
Priority Data
23216759.3
14.12.2023
EP
24199972.1
12.09.2024
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2716 | |
| EPO | Filing, Examination, Granting | 11096 | |
| Japan | Filing, Examination, Granting | 2201 | |
| South Korea | Filing, Examination, Granting | 2145 | |
| USA | Filing, Examination, Granting | 6390 |
Total:
24,548
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The invention relates to antigen-binding polypeptides specifically binding neuraminidase and/or haemagglutinin protein from Influenza B virus resulting in broadly neutralizing IBV antigen-binding polypeptides or antibodies. More specifically the invention relates to immunoglobulin single variable domains specifically binding NA or HA, which upon fusion to bispecific antigen-binding proteins provide for a broader and improved neutralization capacity as compared to a combination of IBV NA- and HA- targeting ISVDs or antibodies. The invention further relates to the use of said antigen-binding proteins for medical purposes, more specifically in prophylactic or therapeutic treatment of a subject, even more specifically to prevent or treat IBV infections.[French]
L'invention concerne des polypeptides de liaison à l'antigène se liant de manière spécifique à la neuraminidase et/ou à la protéine hémagglutinine du virus de la grippe B conduisant à une large neutralisation de polypeptides ou d'anticorps se liant à l'antigène IBV. Plus particulièrement, l'invention concerne des domaines variables uniques d'immunoglobuline se liant de manière spécifique à NA ou HA, qui, lors de la fusion à des protéines de liaison à l'antigène bispécifiques, fournissent une capacité de neutralisation plus large et améliorée par comparaison avec une combinaison d'ISVD ou d'anticorps ciblant NA- et HA d'IBV. L'invention concerne en outre l'utilisation desdites protéines de liaison à l'antigène à des fins médicales, plus précisément dans le traitement prophylactique ou thérapeutique d'un sujet, encore plus précisément pour prévenir ou traiter des infections par le IBV.